Primary sclerosing cholangitis: Time to rethink imaging criteria for early disease detection
- 18 April 2026
- journal article
- Published by Elsevier in Journal of Hepatology
- Vol. 85 (3) , e85-e87
Abstract
No abstract availableFunding Information
- Deutsche Forschungsgemeinschaft (530990199)
- Deutsche Forschungsgemeinschaft (CRC1700)
- Stiftung Michael
- Hamburgischen Stiftung für Wissenschaften, Entwicklung und Kultur Helmut und Hannelore Greve
This publication has 10 references indexed in Scilit:
- British Society of Gastroenterology guidelines on inflammatory bowel disease in adults: 2025Gut, 2025
- LBO-001 Norucholic acid for the treatment of primary sclerosing cholangitis: 96-week analysis of a pivotal phase 3 trialJournal of Hepatology, 2025
- ESGAR consensus statement on MR imaging in primary sclerosing cholangitisEuropean Radiology, 2025
- 24-Nor-ursodeoxycholic acid improves intestinal inflammation by targeting T H 17 pathogenicity and transdifferentiationGut, 2025
- Can a comprehensive gadoxetic acid-enhanced MRI with MRCP be used for early diagnosis, monitoring, and outcome prediction of PSC?European Radiology, 2024
- Inflammatory bowel disease and primary sclerosing cholangitis: One disease or two?Journal of Hepatology, 2023
- EASL Clinical Practice Guidelines on sclerosing cholangitisJournal of Hepatology, 2022
- 24-Norursodeoxycholic acid reshapes immunometabolism in CD8+ T cells and alleviates hepatic inflammationJournal of Hepatology, 2021
- Recommendations on the use of magnetic resonance imaging in PSC‐A position statement from the International PSC Study GroupHepatology, 2017
- Prevalence of Sclerosing Cholangitis Detected by Magnetic Resonance Cholangiography in Patients With Long-term Inflammatory Bowel DiseaseGastroenterology, 2016